Charles Piller

Exploiting Opiophobia, Firm Market Dubious Gene Test for Addiction

When the federal government reversed course last month, deciding not to regulate many genetic tests, one big winner was Proove Biosciences, a Southern California company that markets an unproven "opioid risk" test. Proove claims its test can predict, with 93 percent accuracy, which patients will become addicted to or misuse prescribed opioid pain pills. That's been…

Keep reading... Show less